Malfunction of Nuclease ERCC1-XPF Results in Diverse Clinical Manifestations and Causes Cockayne Syndrome, Xeroderma Pigmentosum, and Fanconi Anemia  by Kashiyama, Kazuya et al.
REPORT
Malfunction of Nuclease ERCC1-XPF Results in Diverse
Clinical Manifestations and Causes Cockayne Syndrome,
Xeroderma Pigmentosum, and Fanconi Anemia
Kazuya Kashiyama,1,2,3,16 Yuka Nakazawa,2,4,16 Daniela T. Pilz,5,16 Chaowan Guo,2,4,16
Mayuko Shimada,2,4 Kensaku Sasaki,2,4 Heather Fawcett,6 Jonathan F. Wing,6 Susan O. Lewin,7
Lucinda Carr,8 Tao-Sheng Li,9 Koh-ichiro Yoshiura,10 Atsushi Utani,11 Akiyoshi Hirano,1
Shunichi Yamashita,3,12 Danielle Greenblatt,13 Tiziana Nardo,14 Miria Stefanini,14 David McGibbon,13
Robert Sarkany,13 Hiva Fassihi,13 Yoshito Takahashi,15 Yuji Nagayama,4 Norisato Mitsutake,2,3
Alan R. Lehmann,6,17,* and Tomoo Ogi2,4,17,*
Cockayne syndrome (CS) is a genetic disorder characterized by developmental abnormalities and photodermatosis resulting from the
lack of transcription-coupled nucleotide excision repair, which is responsible for the removal of photodamage from actively transcribed
genes. To date, all identified causativemutations for CS have been in the two knownCS-associated genes, ERCC8 (CSA) and ERCC6 (CSB).
For the rare combined xeroderma pigmentosum (XP) and CS phenotype, all identifiedmutations are in three of the XP-associated genes,
ERCC3 (XPB), ERCC2 (XPD), and ERCC5 (XPG). In a previous report, we identified several CS cases who did not have mutations in any
of these genes. In this paper, we describe three CS individuals deficient in ERCC1 or ERCC4 (XPF). Remarkably, one of these individuals
with XP complementation group F (XP-F) had clinical features of three different DNA-repair disorders—CS, XP, and Fanconi anemia (FA).
Our results, together with those from Bogliolo et al., who describe XPF alterations resulting in FA alone, indicate a multifunctional
role for XPF.Cockayne syndrome (CS [MIM 216400 and 133540]) is a
rare autosomal-recessive disorder characterized by growth
retardation, microcephaly, impairment of nervous system
development, pigmentary retinopathy, peculiar facies,
and progeria together with abnormal skin photosensi-
tivity.1 On the basis of its clinical severity, CS is classified
into three types: (1) CS type I, the classical (moderate)
form, which is characterized by normal prenatal growth
and the onset of progressive developmental abnormalities
in infancy; (2) CS type II, the more severe (early-onset)
form, in which prenatal developmental abnormalities are
present; and (3) CS type III, a milder form in which proge-
roid symptoms manifest after middle age (see GeneReview
in Web Resources). CS type II is often considered for differ-
ential diagnoses of other microcephalic maldevelopmental
disorders, such as cerebrooculofacialskeletal syndrome
(COFS [MIM 214150], also known as Pena-Shokeir syn-
drome type II) and Warburg Micro syndrome (MIM
600118).2 In addition to these CS classes, there are rare
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The AmXP (MIM 278700, 610651, 278720, 278730, 278740,
278760, and 278780), termed XPCS. Although CS is
commonly associated with sunlight sensitivity, the derma-
tological phenotypes in CS aremilder than those in XP and
skin cancers are not found in CS. XPCS individuals, how-
ever, present with severe skin phenotypes, including severe
photosensitivity, abnormal skin pigmentation, and skin
cancer predisposition, all of which are common to XP indi-
viduals, who also show developmental abnormalities
typical of CS.
XP and CS are associated with deficiencies in nucleotide
excision repair (NER), which removes sunlight-induced UV
photolesions and bulky DNA base adducts from cellular
DNA.3 NER is subdivided into two pathways, global
genome NER (GG-NER) and transcription-coupled NER
(TC-NER), which are distinct in their initial DNA-damage
recognition processes. In contrast to XPCS, which causes
defects in both pathways, CS causes specific defects to
TC-NER.4 To date, all CS (types I, II, and III)-affected indi-
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Figure 1. Three CS Individuals Belong to the ERCC1 and XP-F Complementation Groups
(A) CS1USAU, aged 8 years (left and middle panels) and 16 years (right panels). Note the pigmentation and hypopigmented maculas.
(B) XPCS1CD with features of XP, CS, and FA at 7.5 (left) and 11 years old (right).
(C) Reduction of RRS rates after UV irradiation in three CS cell lines (filled bars, 11 J/m2 UVC; empty bars, no UV). RRS was measured by
ethynyluridine (EU) incorporation and nuclear fluorescence detection (EU assay). 48BR is a normal control, CS20LO, CS1USAU, and
XPCS1CD are CS cells, and XP15BR is affected by XP complementation group A (XP-A).
(D) Reduced level of unscheduled DNA synthesis (UDS) in the CS cells (filled bars, 20 J/m2 UVC; empty bars, no UV).
(legend continued on next page)
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(CSA) or ERCC6 (CSB),5 the products of which function,
together with UVSSA (the product of the gene defective
in UV-sensitive syndrome 3 [UVSS3 (MIM 614640), also
known as UVSS-A])6–8 in the still poorly understood initia-
tion reaction of TC-NER, namely, the processing of the
elongating form of RNA polymerase II stalled at the site
of UV-induced DNA damage. These products thereby facil-
itate further recruitment of TFIIH, XPA, and NER incision
endonucleases, ERCC1-XPF (ERCC4) and XPG (ERCC5),
to carry out the removal of photolesions from actively
transcribed genes.4 In contrast to TC-NER, GG-NER is a
genome-wide repair mechanism, and it shares the later
steps with TC-NER and is deficient in several types of XP
and XPCS.
The lack of TC-NER, as found in CS, can be assessed by
a deficiency in the RRS test, which measures the recovery
of RNA synthesis after UV irradiation. Another marker for
DNA repair activity, the unscheduled DNA synthesis
(UDS) test measures the GG-NER activity as the level of
dNTP incorporation during DNA-repair synthesis after
UV damage. Being negative for RRS and positive for UDS
is diagnostic for CS. We have developed an efficient system
for measuring RRS and UDS activities by using the incor-
poration of ethynyluracil derivatives and automated
fluorescence-based imaging.9,10 In a previous report, we
sequenced all coding exons and their neighboring exon-
intron boundaries of ERCC8, ERCC6, and UVSSA of 61 CS
individuals whose genetic and/or molecular defects had
not yet been determined so that we could evaluate whether
UVSSA mutations might also result in CS phenotypes.6
Although we did not identify any CS pathogenic mutation
in UVSSA, we did identify several CS individuals who did
not appear to have any causal mutations in ERCC8,
ERCC6, or UVSSA, suggesting that additional gene(s)
involved in TC-NER remain to be discovered.
Here, we report on three CS individuals who have
normal ERCC8 and ERCC6 but have a defect in either
ERCC1 or ERCC4 (XPF). In two cases, the affected individ-
uals displayed typical CS clinical features (CS types I and
II). In the third case, the affected individual not only had
the combined XPCS phenotype but also had features of a
third DNA-repair disorder, Fanconi anemia (FA [MIM
227650]). We propose that ERCC1 and ERCC4 be included
as CS- and FA-associated genes.(E) Complete rescue of the RRS deficiency by the infection of recom
ERCC4 cDNA in CS1USAU and XPCS1CD cells (filled bars, 10 J/m2 U
(F) The colony-forming ability of XPCS1CD cells after UVC irradiatio
cell strain with XP complementation group C (XP21BR).
(G) The colony-forming ability of XPCS1CD cells was compared wi
(XP81BR) after treatment with different doses of mitomycin C (MM
(H) MMC sensitivity of different cell strains was determined by MMC
ability to incorporate 3H-thymidine (5 mCi/ml; 3 hr incubation) 3 da
(I) Immunoblotting of ERCC1 and XPF in cells from CS individuals
TFIIH-p89 (XPB) subunit as a loading control. 48BR cells were mock
ERCC4. Asterisks indicate nonspecific bands. RRS was normalized t
that of normal 48BR cells.
Error bars represent the SD of medians of nuclear fluorescencemeasur
triplicate experiments in (F)–(H).
The AmCS20LO (photographs unavailable) was the daughter of
nonconsanguineous parents and had an uneventful ante-
natal period. At 4–6 months of age, she had microcephaly,
micrognathia, and contractures in the knees and elbows
and was hypertonic with a dislocated radial head, deep-
set eyes, and several moderate skeletal abnormalities,
including camptodactyly, adducted thumbs, stiff limbs,
steeply sloping acetabulae, wrist contracture, slender long
bones with mildly flared metaphyses, and moderate
kyphoscoliosis. She displayed brisk reflexes, and there
were no feeding concerns. The karyotype was normal.
Brain MRI at birth indicated a possible polymicrogyria; a
nuclear-magnetic-resonance scan when she was 4 months
old revealed large (>2 cm in depth) bilateral subdurals
but no major visible malformations. An abnormal electro-
encephalogram was noticed at 9 months of age. At
16 months of age, she had nystagmus but no additional
ophthalmic abnormalities; her corneas were completely
clear and showed no evidence of cataracts. The diagnosis
was confirmed as CS type II (early onset) because of RRS
deficiency (see below). She died at the age of 2.5 years.
CS1USAU (Figure 1A) was born at around 41 weeks with
a birth weight of 2.9 kg. He was prenatally diagnosed with
microcephaly. His head circumference was at about the 9th
percentile in the first few months and was lower than the
2nd percentile by 1 year of age. He developed normally for
the first year without obvious abnormalities, except for the
microcephaly. At the age of 5 years, he developed multiple
unusual plantar warts on his hands and forearms. He had
unusual freckling on his hands and the back of his neck
and tended to burn easily and quickly, but did not blister
badly, when he was exposed to sunlight. Since then, he
has been well protected from solar exposure. At 7 years
of age, he had deep-set eyes, progressive scoliosis, and
multiple contractures in his feet; he required lengthening
of the Achilles tendon because of muscle cramps in his
hamstrings and calves. His skin was deeply pigmented
with rashes and flat freckles. He displayed moderate bilat-
eral hearing impairment, especially in the higher tones
(he had normal hearing before the age of 3 years), short
stature (height of 110.4 cm [<2nd percentile] and weight
of 16.3 kg [<3rd percentile]), microcephaly (head circum-
ference of 45.5 cm [<2nd percentile]), and circulatory
problems. He had bilateral astigmatism but no cataracts,binant lentivirus expressing ERCC1 cDNA in CS20LO cells and
VC; empty bars, no UV).
n was compared with that of a normal control (48BR) and that of a
th that of a normal control (1BR) and that of an XP-A cell strain
C) for 10 min.
treatment for 10 min and measurement of their viability by their
ys after treatment.
, ERCC4-deficient XP24BR cells, and normal 48BR cells with the
transfected or transfected with siRNAs targeting either ERCC1 or
o activity in nonirradiated cells. UDS activity was normalized to
ements in quintuplicate samples in (C)–(E) and the SD of means of
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attention deficit hyperactivity disorder, and learning
disability. There were no obvious abnormalities apart
from some delayed myelination on brain MRI at the age
of 3 years, although basal ganglia T1 shortening was
observed at the age of 7 years. He had severe migraines
and headaches. His ambulation lessened over time, and
he needed a gastrostomy-jejunostomy tube for feeding.
Diagnosis of CS was confirmed at the age of 7 years because
of RRS deficiency (see below). He is currently 16 years old.
XPCS1CD (Figure 1B) was the second child of noncon-
sanguineous parents. Intrauterine growth failure was
noted during pregnancy, and therefore labor was induced
at 38 weeks. Her birth weight was between the 0.4th and
2nd percentiles, her developmental milestones were glob-
ally delayed, and she required speech therapy. By
18 months of age, she was reported to sunburn with min-
imal sun exposure in both winter and summer months in
the UK. Her parents described that sunburns would
develop 24 hr after exposure, peak at 2–3 days, and resolve
after 10–14 days. As a result, she was carefully photopro-
tected and did not have any further sunburn reactions after
4 years of age. When she was 5 years old, she developed
progressive bilateral sensorineural deafness, and 2 years
later, she presented with worsening ataxia, tremor, and
weakness. She had short stature and significant micro-
cephaly. At the age of 7.5 years (Figure 1B, left), her height
was 1.4 cm below the 0.4th percentile and her occipitofron-
tal head circumference (OFC) was 6.5 cm below the 0.4th
percentile. By the age of 6 years, shewas thrombocytopenic
and neutropenic, coinciding with treatment for recurrent
infections. Her blood film showed irregularly shaped cells,
and she gradually became pancytopenic with transfusion
dependence by the age of 9 years. Renal impairment was
detected at the age of 10 years, when she presented with
hypertension, nephrotic range proteinuria, and rising
serum creatinine. The karyotype was normal.
Upon examination at 11 years of age (Figure 1B, right),
she was microcephalic with an OFC well below the 0.4th
percentile and had extremely short stature. She had
deep-set eyes, a prominent nose, small teeth, and freckling
over the nose and cheeks. There was marked palmar ery-
thema, and extensive plane warts were seen on the arms.
Her skin had an aged appearance, particularly over the
dorsal hands. She had five cafe´-au-lait macules. Her neuro-
logical examination highlighted a resting tremor, head
titubation, and an ataxic gait. She demonstrated saccadic
eye movements and an element of vertical nystagmus.
There was subtle pyramidal tract weakness distally with
extensor plantar reflexes. Sensation was intact. Ophthal-
mological examination revealed hypermetropia and bilat-
eral blepharitis, but no other ocular abnormalities. MRI
of the brain showed increased signal in the peritrigonal
white-matter bilaterally. A renal biopsy and bone marrow
aspirate were performed under general anesthesia (when
she was 11 years old). The bone marrow showed a pro-
foundly hypocellular sample in which all three lineages
were present, blast percentage was <1%, and dysplasia810 The American Journal of Human Genetics 92, 807–819, May 2, 2was minimal. No clonal cytogenetic abnormalities were
detected. A simultaneous full blood count showed a hae-
moglobin level of 9.4 g/dl (11.5–15.5 g/dl), a red blood
cell count of 2.98 3 1012/l (3.40–5.20 3 1012/l), and a
mean corpuscular volume of 95.0 fl (80.0–98.0 fl). Studies
of liver function were normal. The renal biopsy showed
areas of focal segmental glomerular sclerosis and evident
thickening of the capillary basement membrane. There
was a background of interstitial fibrosis and tubular atro-
phy with glomerular shrinkage. She died at the age of
12 years after acute deterioration of her renal function. A
postmortem examination was not done.
Many of her features were characteristic of CS,11
although pancytopenia and renal failure are not usually
associated with this disorder. The exaggerated and pro-
longed sunburn reactions together with progressive freck-
ling at sun-exposed sites were suggestive of XP, whereas
the pancytopenia, bonemarrow findings, and recurrent in-
fections are features often seen in FA.
To determine DNA-repair activities in the CS individuals’
cells, we established dermal fibroblast cultures from skin
biopsies. Written informed consent was obtained from
the individuals’ families, and the experiments were carried
out in accordance with the local ethical standards (Naga-
saki University Ethical, Legal, and Social Implications
committee). We first measured the RRS rate after exposure
to 10 J/m2 UVC irradiation.6,9,10 RNA-synthesis activity
was significantly reduced in all three CS cell lines
compared with normal cells (Figure 1C), indicating a defi-
ciency in TC-NER activity, as expected for CS cells. We also
measured UDS, a mark of GG-NER activity,6,9,10 which is
not normally affected in CS cells.12 We found a significant
reduction in UDS rates in all three CS cell lines (Figure 1D).
These results imply that the CS individuals have defective
GG-NER and TC-NER pathways, and we therefore pre-
sumed that, unlike other CS individuals, they carry defects
in genes that commonly function in both the TC-NER and
GG-NER pathways. Consequently, we anticipated that
these three CS individuals might carry mutations either
in ERCC3 (XPB), ERCC2 (XPD), ERCC4, or ERCC5 (XPG)
or in ERCC1, and we assayed complementation of the
RRS defects by infecting the CS cells lines with recombi-
nant lentiviruses expressing one of these NER-related
cDNAs6 (Figure 1E). The RRS defects were dramatically
and specifically restored when CS20LO cells were infected
with lentiviruses expressing ERCC1 and when CS1USAU
and XPCS1CD cells were infected with ERCC4 cDNA, but
not when the cells were infected with other viruses
(Figure 1E). We conclude that CS20LO is assigned to
the ERCC1 complementation group and that, likewise,
CS1USAU and XPCS1CD are assigned to XP complementa-
tion group F (XP-F).
A hallmark of cells from individuals with FA is a specific
defect in the repair of DNA interstrand crosslinks (ICLs).
The ERCC1-XPF complex, which is uniquely among the
NER proteins, is also involved in ICL repair.13,14 Because
several clinical features of XPCS1CD are characteristic of013
FA, we measured the survival of this individual’s cells after
exposure to UV irradiation and to the crosslinking agent
mitomycin C (MMC). Figure 1F shows that cells from
XPCS1CD are as sensitive to UV irradiation as those from
an XP control. In contrast, the XP control cells (in this
case, from group A) are, as reported in the literature,15
not sensitive to MMC, whereas XPCS1CD cells are much
more sensitive (Figure 1G). Furthermore, chromosome-
breakage studies on blood showed increased sensitivity to
MMC and an elevated level of chromosome damage
upon exposure to the alkylating agent DEB (1,2,3,4-die-
poxybutane). However, the levels were lower than ex-
pected for a diagnosis of FA (data not shown). In view of
these observations, we also examined the MMC sensitivity
of CS1USAU and CS20LO cells and found that the former
were also very sensitive to MMC, whereas the latter were
marginally, if at all, sensitive (Figure 1H).
ERCC1 is needed for stabilizing and enhancing XPF
endonuclease activity,16,17 and indeed, using immunoblot-
ting, we observed a significant reduction in the expression
level of XPF concurrently with the reduction of ERCC1
expression in CS20LO cells (Figure 1I). In contrast, XPF
and ERCC1 levels were modestly reduced in CS1USAU
and XPCS1CD cells (Figure 1I).
To determine the genetic changes in the three CS indi-
viduals, we carried out (1) PCR-based gDNA amplification
of the exons and neighboring exon-intron boundaries of
ERCC1 from CS20LO cells and of ERCC4 from CS1USAU
cells and subsequent direct sequencing of the amplified
gDNA fragments and (2) RT-PCR of mRNA and sequencing
of the cDNA from XPCS1CD cells. In CS20LO cells, a
homozygous mutation, c.693C>G, in exon 7 of ERCC1
(RefSeq accession number NM_001983.3) resulted in
amino acid substitution p.Phe231Leu, located in the
C-terminal XPF-interacting helix-hairpin-helix (HhH)
domain (Figure 2A). ERCC1 pathogenic changes identified
in NER-deficient diseases and in other genetic disorders are
extremely rare; only two cases have been reported.18,21
Individual 165TOR,21 who had clinical features overlap-
ping those of CS and was diagnosed with a severe form
of COFS, was heterozygous for the ERCC1 c.693C>G
(p.Phe231Leu) mutation found in our CS individual.
In 165TOR, the other ERCC1 pathogenic allele was
c.472C>T (p.Gln158*); however, the mutated transcript
is presumed to be subject to nonsense-mediated mRNA
decay (NMD). XP202DC18 was a XP individual who devel-
oped progressive neurodegeneration during adolescence
and died at the age of 37 years. He was compound hetero-
zygous for nonsense substitution p.Lys226* near the C ter-
minus and splice-site mutation c.604-26G>A, which
might have affected the expression level of wild-type
ERCC1. In this individual, a low amount of the wild-type
ERCC1 allele expression might have been sufficient to
ameliorate the more severe aspects of the disorder.
CS1USAU cells had two heterozygous mutational
changes in ERCC4 (RefSeq NM_005236.2): (1) an exon 4
mutation, c.706T>C, causing an amino acid substitution,The Amp.Cys236Arg, located in the N-terminal large SF2 heli-
case domain and (2) an exon 8 frameshift insertion,
c.1730_1731insA, which generated a premature stop
codon, p.Tyr577* (Figure 2B). XPCS1CD had two ERCC4
heterozygous mutations, c.706T>C and c.1765C>T, re-
sulting in changes p.Cys236Arg (the same mutation as
we found in CS1USAU) and p.Arg589Trp (previously found
in three XP individuals) (Figure 2C), respectively.18 Previ-
ously identified alterations in ERCC1 and XPF, together
with those identified in this paper, are shown in Figure 2D.
XPF pathogenic alterations are normally associated with
mild XP cases without severe developmental abnormal-
ities.18 There has been one exceptional case, XFE progeroid
syndrome (MIM 610965). The affected individual,
XP51RO, carried a homozygous mutation resulting in a
p.Arg153Pro change in the SF2 domain of XPF.22 In all re-
ported cases with mild XP-F, the pathogenic mutations are
hypomorphic and there is a substantial amount of residual
XPF in the cells; however, in the XFE individual cells,
XPF expression was severely reduced.22 In contrast, in
CS1USAU and XPCS1CD cells, a substantial amount of
XPF remained (Figure 1I), suggesting that the pathogenic
allele is fully expressed and the altered protein is stable
(also see later purification of the ERCC1-XPF complex).
These observations indicate that p.Cys236Arg causes XPF
dysfunction and confers a CS phenotype on individuals
CS1USAU and XPCS1CD.
XPF and ERCC1 form a heterodimeric structure-specific
endonuclease, the ERCC1-XPF complex, which cleaves
on the 50 side of the UV-damaged DNA at the incision
step of NER.23–25 The proteins form a complex through
their C-terminal HhH domains and stabilize the counter-
part when in a complex. To test whether the p.Phe231Leu
altered ERCC1 and the p.Cys236Arg altered XPF form
proper ERCC1-XPF complexes, we introduced the altered
proteins (V5-tagged) into 293FT cells and performed
immunoprecipitation to check the binding affinity be-
tween ERCC1 and XPF. Although the ERCC1 p.Phe231Leu
substitution is located in the XPF-binding HhH domain
and the residue interfaces with two alpha helices of the
XPF HhH domain, the altered ERCC1 binding capacity to
XPF was unaffected by the substitution (Figure 3A).
Similarly, we observed no significant decrease in copre-
cipitation of wild-type ERCC1 in the complex when
p.Cys236Arg XPF was expressed (Figure 3B). The ERCC1-
XPF complex also interacts with TFIIH, as shown by both
in vitro and in vivo experiments.26 We therefore tested
the binding affinity of altered ERCC1 and XPF with the
XPB-p89 subunit of TFIIH. Although there was no signifi-
cant reduction in binding affinity of p.Phe231Leu ERCC1
expressed in 293FT cells (Figure 3A), we observed, after
UV irradiation, less p89 in immunoprecipitates from
cells expressing p.Cys236Arg XPF than from wild-type
controls (Figure 3B). Recent studies also demonstrated
that the three known structure-specific endonuclease
complexes (SSEs)—ERCC1-XPF, SLX4 (FANCP)-SLX1, and
MUS81 (SLX3)-EME1 (SLX2)—interact with each other inerican Journal of Human Genetics 92, 807–819, May 2, 2013 811
Figure 2. Locations of the ERCC1 and ERCC4 Mutations Identified in the CS Cells and in Known NER Disorders
(A) The homozygous c.693C>G single-nucleotide variant (SNV) in ERCC1 exon 7 in the CS individual, CS20LO; the altered amino acid,
Phe231, is shown in red.
(B) The heterozygous c.706T>C SNV in ERCC4 exon 4 and the 1 base insertion, c.1730_1731insA, in ERCC4 exon 8 are identified in the
CS individual, CS1USAU. The altered amino acids, Cys236 and Tyr577, are shown in red.
(legend continued on next page)
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crosslink-repair pathways. Importantly, mutations in SLX4
have been identified in several FA individuals, and SLX4
acts as a scaffold and plays a key role in the coordination
of these interactions.27–29 We therefore tested whether
one of these interactions, namely the binding affinity
of the altered protein with MUS81 (Figure 3B), is com-
promised in cells expressing the XPF p.Cys236Arg sub-
stitution. There was no impact on the binding affinity,
suggesting that this was not the cause of the FA features
observed in XPCS1CD.
To further test whether the altered ERCC1 and XPF pro-
teins retain any DNA-repair functions, we performed
complementation analyses of the RRS defects by express-
ing mutant ERCC1 and ERCC4 cDNAs in the ERCC1- and
XPF-deficient CS cells, respectively (Figure 3C). Consistent
with the previous report describing a correction of UV
sensitivity after transfection with the ERCC1 c.693C>G
(p.Phe231Leu) pathogenic mutant cDNA into ERCC1-defi-
cient 165TOR cells,21 we observed that RRS in the ERCC1-
deficient CS20LO cells was fully restored upon infection
with the lentivirus expressing c.693C>G (p.Phe231Leu)
mutant ERCC1 cDNA, whereas expression of the
p.Cys236Arg altered XPF failed to restore RRS levels of
the XPF-deficient CS1USAU cells.
We then purified recombinant ERCC1-XPF complexes
and determined their endonuclease activity. As observed
in Figure 1I, the altered p.Cys236Arg XPF complex was
stable (Figure 3D). Because stem-loop structures are good
substrates for the ERCC1-XPF complex,30 we performed
in vitro incision assays with fluorescent-labeled DNA
templates containing a 12 bp stem-dT22-loop.19,30 We
observed significant reduction of the endonuclease activity
of the p.Cys236Arg altered complex (Figure 3E).
These data indicate that XPF malfunction, caused by the
lack of proper interaction between TFIIH and ERCC1-XPF,
and a substantial reduction of the stem-loop incision activ-
ity of the endonuclease complex cause the CS and FA phe-
notypes in CS1USAU and XPCS1CD, whereas the reason
for ERCC1 deficiency in CS20LO cells remains unclear.
Unlike NER-associated genes that are responsible exclu-
sively for CS and UVSS phenotypes (i.e., ERCC8, ERCC6,
and UVSSA), ERCC4 and ERCC1 are presumably indispens-
able for fetal development because there is no known indi-
vidual carrying homozygous or compound-heterozygous
null mutations in either of the genes. Given that we found
that the p.Phe231Leu altered ERCC1 retains normal NER
function, we decided to determine the precise expression
levels of the mutant ERCC1 and ERCC4 alleles identified
in two of the CS individuals. We undertook allele-specific
quantitative RT-PCR (qRT-PCR) with sets of primers that
selectively amplify the wild-type or the mutant ERCC1(C) The heterozygous c.706T>C SNV in ERCC4 exon 4 and the hete
Cys236 and Arg589, are shown in red.
(D) The structure of ERCC1 and XPF and the amino acid alterations
colors are as follows: XP, black; COFS, blue; XFE, green; and CS or X
alleles.
The Amand ERCC4 cDNAs (Table 1). In CS20LO cells, primer set
ERCC1-WT and ERCC1-Rv1 allowed specific amplification
of the wild-type ERCC1 allele (Figure 4A, left), whereas
another set of primers, ERCC1-p.Phe231Leu and ERCC1-
Rv1, amplified the c.693C>G (p.Phe231Leu) allele in
exon 7 (Figure 4A, middle); primers ERCC1-com1 and
ERCC1-Rv1 amplified both the wild-type and the mutant
alleles (Figure 4A, right). We observed a very low level
(50-fold < wild-type) of expression of the ERCC1
c.693C>G (p.Phe231Leu) allele in CS20LO cells (Figure 4A,
middle and right), suggesting that the ERCC1-null pheno-
type can be ascribed to this drastic attenuation of ERCC1
mRNA expression. Subsequently, expression of the wild-
type and the two mutated ERCC4 alleles in CS1USAU cells
was examined. Similarly to how we quantified ERCC1
mRNA, we designed sets of primers to specifically amplify
the c.706T>C (p.Cys236Arg) allele located in exon 4
(Figure 4B, middle) and the c.1730_1731insA (p.Tyr577*)
allele in exon 8 (Figure 4C, middle), as well as their corre-
sponding wild-type alleles (Figure 4B and 4C, left). We
confirmed the expression of the c.706T>C (p.Cys236Arg)
allele specifically in CS1USAU cells (Figure 4B, middle
and right) with primers XPF-p.Cys236Arg and XPF-Rv1,
whereas the c.1730_1731insA (p.Tyr577*) allele, measured
by primers XPF-p.Tyr577* and XPF-Rv2, was subjected to
NMD, because its expression level was very low in the CS
cells (Figure 4C, middle). Given these qRT-PCR data and
the protein expression levels in the CS cells (Figure 1I),
we conclude that the ERCC1-deficiency phenotype in
CS20LO results from a very low level of expression of the
mutant allele and that the XPF deficiency in CS1USAU
and XPCS1CD is mainly caused by protein malfunction.
A summary of our findings is presented in Table 2.
We have identified three CS individuals who carry path-
ogenic mutations in either ERCC1 or ERCC4. Approxi-
mately 25 XP-F individuals have been described in the
literature.18 The majority of them are XP individuals,
who, compared with individuals affected by XP comple-
mentation group C, have relatively mild skin problems
and skin cancers that appear relatively later in life. Only
XFE individual XP51RO had a much more severe pheno-
type.22 Like our CS individuals, he had short stature,
cachexia, and microcephaly. He had mild learning diffi-
culties, hearing loss, and visual impairment. He was sensi-
tive to the sun from birth and had dry, atrophic skin and
irregular pigmentation on sun-exposed areas. Laboratory
studies indicated renal insufficiency, and he died at the
age of 16 years from severe pneumonia and multisystem
organ failure. This individual had many features in com-
mon with XPCS1CD, but there was no report of pancyto-
penia. He was homozygous for p.Arg153Pro in XPF.rozygous c.1765C>T SNV in XPCS1CD. The altered amino acids,
reported here and published previously.18–20 The cases shown in
PCS, red. Superscripted 1 and 2 designate the number of discrete
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Figure 3. ERCC1 and XPF Interaction in the CS Cells
(A) V5-tagged wild-type and p.Phe231Leu altered ERCC1 interactions with the endogenous wild-type XPF were assayed by immunopre-
cipitation either without UV irradiation or 1 hr after 10 J/m2 of UV irradiation.
(B) V5-tagged wild-type and p.Cys236Arg altered XPF were expressed in 293T cells, and interactions with the endogenous wild-type
ERCC1 were assayed by immunoprecipitation from extracts of cells either without UV irradiation or 1 hr after 10 J/m2 of UV irradiation.
(legend continued on next page)
814 The American Journal of Human Genetics 92, 807–819, May 2, 2013
Table 1. Primers Used for Allele-Specific Amplifications
Primer Designation Primer Sequence
ERCC1-WT1 50- CTGATGGAGAAGCTAGAGCAGGACTTC-30
ERCC1-p.Phe231Leu 50- CTGATGGAGAAGCTAGAGCAGGACTTG-30
ERCC1-com1 50- CCTGATGGAGAAGCTAGAGCAGGACTT-30
ERCC1-Rv1 50- GGTCAGACATTCAGTCACCCGC-30
XPF-WT1 50- GACTGCTATACTGGACATTTTAAATGCAT-30
XPF-p.Cys236Arg 50- GACTGCTATACTGGACATTTTAAATGCAC-30
XPF-com1 50- AGACTGCTATACTGGACATTTTAAATGCA-30
XPF-Rv1 50- TCCAAGCTGGTGCCACAAA-30
XPF-WT2 50- AGGGTACTACATGAAGTGGAGCCAAGAT
AC-30
XPF-p.Tyr577* 50- AGGGTACTACATGAAGTGGAGCCAAGAT
AA-30
XPF-com2 50- AAGGGTACTACATGAAGTGGAGCCAAGA
TA-30
XPF-Rv2 50- CCCTCAGAGGTTTCCCAGGC-30Somewhat surprisingly, the previously reported ERCC1-
deficient severe COFS individual was compound heterozy-
gous for the same pathogenic p.Phe231Leu change
together with a termination substitution, p.Gln158*,21
whereas our CS type II individual was homozygous for
this substitution. Because the p.Phe231Leu altered
ERCC1 retained normal function, differences in severity
of the clinical features might be explained by the dosage
of ERCC1 expression. We hypothesize that the relatively
milder clinical features observed in our CS individual
might be due to the fact that the biallelic expression ofInteractions were detected by immunoblotting with antibodies aga
2G10/3, Santa Cruz), ERCC1 (8F1, Santa Cruz), and XPF (Ab-1, T
(10% load); and IP, immunoprecipitate.
(C) Rescue of the RRS deficiency was assayed by the infection of reco
and ERCC4 cDNAs (filled bars, 11 J/m2 UV; empty bars, no UV). RRS w
the SD of medians of nuclear fluorescence measurements in quintup
(D) Purification of the recombinant ERCC1-XPF complexes. FLAG-t
coexpressed with the 6 3 His-tagged ERCC1 (C terminus) in 293T
Tris-HCl, 150 mM KCl, 1 mM EDTA, 1% NP-40, 10% glycerol, 0.25 m
affinity purification was performedwithmouse anti-FLAG IgG-conjug
resin (Clontech). Cell lysates were incubated with anti-FLAG agaros
Tris-HCl, 1 M KCl, 0.1 mM EDTA, 10% glycerol, PIC, pH 7.5) an
10mM imidazole, PIC, pH 7.5). Binding proteins were eluted with star
were incubated with TALONmetal affinity resin (Clontech) and were
NaCl, 10% glycerol, 10 mM Imidazole, PIC, pH 7.5) and buffer B (40
pH 7.5). The purified complex was sequentially eluted with elution
Imidazole, PIC, pH 7.5) and elution buffer B (40 mMHEPES, 100 mM
was dialyzed against GF buffer (25 mM HEPES, 150 mM NaCl, 10%
trated. The purified complexes were resolved by SDS-PAGE and detec
plexes was assessed by immunoblotting with antibodies against the F
endogenous XPF was detected.
(E) Endonuclease activity of the wild-type and altered ERCC1-XPF c
dT22-loop DNA templates. Either 30-fluorescein- or 50-Cy5-labeled o
30) were purchased from SIGMA and self-annealed in TE buffer. Nuc
templates and 0, 25, 50, 100 ng of the purified ERCC1-XPF complexes
40 mMNaCl, 10% glycerol, 0.5 mM beta-mercaptoethanol, and 0.1 m
reaction mixtures were incubated at 30C for 1 hr. Samples were sepa
analyzed by a Typhoon imager (GE).
The Amthe mutated ERCC1 allele produced twice the level of
functional ERCC1 in the CS individual as in the COFS
individual. This idea is also supported by the observation
that the other ERCC1-deficient XP individual, who dis-
played milder clinical features, harbored a splice-site muta-
tion that most likely allowed readthrough of a significant
amount of normal protein.
We identified a heterozygous XPF alteration,
p.Cys236Arg, in CS individuals CS1USAU and XPCS1CD.
CS1USAU displayed mild skin problems in the range
defined by normal CS features, but he has been very well
protected from sun exposure. He displayed hypopig-
mented macules (Figure 1A), which are typical of XP and
often occur on the limbs and other sun-exposed sites
before ‘‘freckling.’’ In view of this and his early freckling,
it seems appropriate to classify this affected individual as
also having the combined XPCS phenotype. However,
XPCS1CD, but not CS1USAU, also exhibited hematologi-
cal abnormalities characteristic of FA. Surprisingly, the
second allele in the milder individual, CS1USAU, was a
functionally null termination mutation, which was sub-
jected to NMD, whereas in the more severely affected
XPCS1CD, the second allele harbored c.1765C>T
(p.Arg589Trp), which is found in several XP individuals
and results in mislocalization of the ERCC1-XPF complex
to the cytoplasm and thus causes a severe XP phenotype
when combined with certain other alleles.19 XP32BR
(with p.Arg589Trp and p.Pro379Ser) was a mildly affected
XP individual in his teens and had no neurological prob-
lems; XP24BR (with p.Arg589Trp and p.Arg799Trp) was
also mildly affected but is now showing some abnormal
neurological and CS-like facial features in her 40s (our un-
published data); AS871 (with p.Arg589Trp resulting frominst the V5-tagged ERCC1 and XPF (1H6, MBL), MUS81 (MTA30
hermo scientific). Abbreviations are as follows: CL, crude lysate
mbinant lentivirus expressing either wild-type or mutant ERCC1
as normalized to activity in nonirradiated cells. Error bars represent
licate samples.
agged (C terminus) wild-type and p.Cys236Arg altered XPF were
cells. The cells were harvested and lysed in lysis buffer (50 mM
M PMSF, protease-inhibitor cocktail [PIC, Roche], pH 7.5). Tandem
ated beads (M2 agarose, SIGMA) followed by TALONmetal affinity
e beads and were subsequently washing with salt buffer (20 mM
d starting buffer (20 mM Tris-HCl, 800 mM KCl, 10% glycerol,
ting buffer containing 1mg/ml FLAGpeptide. The eluted fractions
then sequentially washed with buffer A (40 mMHEPES, 1,000mM
mM HEPES, 100 mM NaCl, 10% glycerol, 10 mM Imidazole, PIC,
buffer A (40 mM HEPES, 100 mM NaCl, 10% glycerol, 100 mM
NaCl, 10% glycerol, 300 mM Imidazole, pH 7.5). Purified complex
glycerol, 5 mM beta-mercaptoethanol, PIC, pH 8.0) and concen-
ted by silver staining (100 ng of total protein). Purity of the com-
LAG (MBL) and 6 3 His (MBL) tags, as well as ERCC1 and XPF. No
omplexes was determined with fluorescently labeled 12 bp stem-
ligonucleotides (50-GCCAGCGCTCGG-dT22-CCGAGCGCTGGC-
lease incision reactions were performed on 200 fmol of the DNA
in a total volume of 15 ml nuclease reaction buffer (25 mMHEPES,
g/ml BSA and either 2 mMMgCl2 or 0.4 mMMnSO4, pH 8.0). The
rated on urea-denatured 15% PAGE, and the cleaved products were
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Figure 4. Expression of the Pathogenic Alleles in the CS Cells
Total RNA was extracted with ISOGEN reagent (NIPPON GENE) according to the manufacturer’s instruction. One microgram of total
RNA was reverse transcribed with a high-capacity RNA-to-cDNA kit (Applied Biosystems, Life Technologies). Quantitative PCR amplifi-
cation and real-time detection were carried out in a Thermal Cycler Dice Real-Time System (TaKaRa Bio) with SYBR Premix Ex TaqII
(TaKaRa Bio) and a QuantiTect SYBR Green PCR kit (QIAGEN). For each sample, relative mRNA levels were normalized against
HPRT1 mRNA expression. Error bars represent the SD of means of triplicate experiments.
(A) Selective quantitative amplification of the wild-type and the mutated c.693C>G (p.Phe231Leu) ERCC1 alleles in CS20LO cells and
normal 48BR cells. Allele-specific primers selectively amplified the wild-type (c.693C) allele (ERCC1-WT1 and ERCC1-Rv1, left panel),
the CS pathogenic mutant (c.693C>G) allele (ERCC1-p.Phe231Leu and ERCC1-Rv1, middle panel), and both alleles at once (ERCC1-
com1 and ERCC1-Rv1, right panel).
(B) Selective quantitative amplification of the wild-type and the mutated c.706T>C (p.Cys236Arg) ERCC4 alleles in CS1USAU cells and
normal 48BR cells. Allele-specific primers selectively amplified the wild-type (c.706T) allele (XPF-WT1 and XPF-Rv1, left panel), the CS
(legend continued on next page)
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Table 2. Summary of Phenotypes of CS Cells
Individual
CS20LO CS1USAU XPCS1CD
RRS – – –
UDS – – –
Virus complementation with ERCC1 wild-type cDNA (RRS)a þ – –
Virus complementation with ERCC4 wild-type cDNA (RRS)a – þ þ
XPF expression – þ/– þ/–
ERCC1 expression – þ/– þ/–
Protein alteration ERCC1 p.Phe231Leu XPF p.Cys236Arg
and p.Tyr577*
XPF p.Cys236Arg and
p.Arg589Trp
ERCC1-XPF IP þ þ þ (p.Cys236Arg)
p89 IP þ þ/– þ/– (p.Cys236Arg)
Virus complementation with ERCC1 c.693C>G (p.Phe231Leu) cDNA (RRS)a þ ND ND
Virus complementation with ERCC4 c.706T>C (p.Cys236Arg) cDNA (RRS)a ND – ND
ERCC1-XPF nuclease activity ND – (p.Cys236Arg) – (p.Cys236Arg)
Mutant mRNA level V low þ/– ND
Abbreviations are as follows: þ, normal; –, defective or absent; þ/–, intermediate; IP, immunoprecipitation; ND, not done.
aEffect of the indicated cDNA on the RRS response.the deletion of exon 3) had severe skin symptoms and
neurodegeneration.19 The reason why a partially func-
tional allele (c.1765C>T [p.Arg589Trp]) in XPCS1CD re-
sults in a more severe phenotype than the null allele in
CS1USAU is currently unclear.
Mice homozygous for a frameshift mutation in Ercc4
(Xpf) die by 3 weeks of age.31 Likewise, mice in which
Ercc1 has been deleted die soon after birth.32,33 They
develop progressive neurodegeneration, leucopenia and
thrombocytopenia,22 and impaired liver function.32
Many of these characteristics resemble those of XPCS1CD.
Pancytopenia is a hallmark of FA, a disorder associated
with cellular hypersensitivity to DNA-ICL-inducing
agents.34 Recent data have indicated that endogenous
aldehydes generate DNA damage that requires the FA
pathway for resolution.35 We therefore favor the expla-
nation that pancytopenia arises from a defect in the
response to such crosslinkers; this defect is common to
the FA individuals and XPCS1CD (Figure 1G). Support
for this idea comes from Bogliolo et al.,36 who report on
two FA individuals with mutations in ERCC4 but without
features of CS or XP.
Finally, our results demonstrate that ERCC4 and
ERCC1 must be added to the list of genes in which defectspathogenic mutant (c.706T>C) allele (XPF-p.Cys236Arg and XPF-Rv1
right panel).
(C) Selective quantitative amplification of the wild-type and the c.
selectively amplified the wild-type (c.1731C) allele (XPF-WT2 and X
allele (XPF-p.Tyr577* and XPF-Rv2, middle panel), and both alleles
used for the qRT-PCR experiments are depicted on the right-hand si
Primers used for the qPCR are listed in Table 1.
The Amcan result in either CS or the combined XP-CS-FA
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